Literature DB >> 9321519

Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.

J G Slatter1, P Su, J P Sams, L J Schaaf, L C Wienkers.   

Abstract

Human hepatic microsomes were used to investigate the carboxylesterase-mediated bioactivation of CPT-11 to the active metabolite, SN-38. SN-38 formation velocity was determined by HPLC over a concentration range of 0.25-200 microM CPT-11. Biphasic Eadie Hofstee plots were observed in seven donors, suggesting that two isoforms catalyzed the reaction. Analysis by nonlinear least squares regression gave KM estimates of 129-164 microM with a Vmax of 5.3-17 pmol/mg/min for the low affinity isoform. The high affinity isoform had KM estimates of 1.4-3.9 microM with Vmax of 1.2-2.6 pmol/mg/min. The low KM carboxylesterase may be the main contributor to SN-38 formation at clinically relevant hepatic concentrations of CPT-11. Using standard incubation conditions, the effects of potential inhibitors of carboxylesterase-mediated CPT-11 hydrolysis were evaluated at concentrations >/= 21 microM. Positive controls bis-nitrophenylphosphate (BNPP) and physostigmine decreased CPT-11 hydrolysis to 1.3-3.3% and 23% of control values, respectively. Caffeine, acetylsalicylic acid, coumarin, cisplatin, ethanol, dexamethasone, 5-fluorouracil, loperamide, and prochlorperazine had no statistically significant effect on CPT-11 hydrolysis. Small decreases were observed with metoclopramide (91% of control), acetaminophen (93% of control), probenecid (87% of control), and fluoride (91% of control). Of the compounds tested above, based on these in vitro data, only the potent inhibitors of carboxylesterase (BNPP, physostigmine) have the potential to inhibit CPT-11 bioactivation if administered concurrently. The carboxylesterase-mediated hydrolysis of alpha-naphthyl acetate (alpha-NA) was used to determine whether CPT-11 was an inhibitor of hydrolysis of high turnover substrates of carboxylesterases. Inhibition of alpha-NA hydrolysis by CPT-11 was determined relative to positive controls BNPP and NaF. Incubation with microsomes pretreated with CPT-11 (80-440 microM) decreased alpha-naphthol formation to approximately 80% of control at alpha-NA concentrations of 50-800 microM. The inhibitors BNPP (360 microM) and NaF (500 microM) inhibited alpha-naphthol formation to 9-10% of control and to 14-20% of control, respectively. Therefore, CPT-11-sensitive carboxylesterase isoforms may account for only 20% of total alpha-NA hydrolases. Thus, CPT-11 is unlikely to significantly inhibit high turnover, nonselective substrates of carboxylesterases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9321519

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

1.  Proteomic analysis of cell lines to identify the irinotecan resistance proteins.

Authors:  Xing-Chen Peng; Feng-Ming Gong; Meng Wei; Xi Chen; Ye Chen; Ke Cheng; Feng Gao; Feng Xu; Feng Bi; Ji-Yan Liu
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

2.  Discovery and Characterization of the Biflavones From Ginkgo biloba as Highly Specific and Potent Inhibitors Against Human Carboxylesterase 2.

Authors:  Yun-Qing Song; Rong-Jing He; Dan Pu; Xiao-Qing Guan; Jin-Hui Shi; Yao-Guang Li; Jie Hou; Shou-Ning Jia; Wei-Wei Qin; Sheng-Quan Fang; Guang-Bo Ge
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

3.  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

Authors:  Masato Horikawa; Yukio Kato; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

4.  Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals.

Authors:  Zhe-yi Hu; Xiu-xue Li; Fei-fei Du; Jun-ling Yang; Wei Niu; Fang Xu; Feng-qing Wang; Chuan Li; Yan Sun
Journal:  Acta Pharmacol Sin       Date:  2013-09-23       Impact factor: 6.150

5.  ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Authors:  M Li; E L Seiser; R M Baldwin; J Ramirez; M J Ratain; F Innocenti; D L Kroetz
Journal:  Pharmacogenomics J       Date:  2016-11-15       Impact factor: 3.550

6.  Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.

Authors:  Pankajini Mallick; Sumit Basu; Bhagavtula Moorthy; Romi Ghose
Journal:  Toxicol In Vitro       Date:  2017-02-27       Impact factor: 3.500

Review 7.  Experience with irinotecan for the treatment of malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; David A Reardon; Henry S Friedman
Journal:  Neuro Oncol       Date:  2008-09-10       Impact factor: 12.300

8.  The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions.

Authors:  Robert B Parker; S Casey Laizure
Journal:  Drug Metab Dispos       Date:  2009-11-17       Impact factor: 3.922

9.  CPT-11 Chemotherapy Rescued A Patient with Atypical Sclerosing Epithelioid Fibrosarcoma from Emergent Condition.

Authors:  Chun-Hua Pan; Xi-Qun Han; Jian-Sheng Li
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

10.  Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

Authors:  Michael D Prados; W K A Yung; Kurt A Jaeckle; H Ian Robins; Minesh P Mehta; Howard A Fine; Patrick Y Wen; Timothy F Cloughesy; Susan M Chang; M Kelly Nicholas; David Schiff; Harry S Greenberg; Larry Junck; Karen L Fink; Kenneth R Hess; John Kuhn
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.